Literature DB >> 9373661

Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma.

V Desakorn1, K Silamut, B Angus, D Sahassananda, K Chotivanich, P Suntharasamai, J Simpson, N J White.   

Abstract

Plasmodium falciparum histidine rich protein 2 (PfHRP2) antigen was measured semi-quantitatively in whole blood, plasma, and supernatants and red blood cells of cultures in vitro using the dipstick ParaSight-F test and also by a quantitative antigen-capture enzyme-linked immunosorbent assay (ELISA). In vitro, PfHRP2 was secreted mainly during the second half of the asexual cycle with a marked rise during schizont development and rupture. The total PfHRP2 secreted before schizogony corresponded to approximately 4% of that contained in the red blood cells. In samples from 55 patients with acute falciparum malaria, the level of detection by ELISA corresponded to parasitaemias of 100/microL for whole blood and 1600/microL for separated plasma. Whole blood PfHRP2 levels were correlated significantly with admission parasitaemia (r = 0.76, P < 0.0001) and the stage of parasite development (r = 0.43, P < 0.01). Although whole blood PfHRP2 concentrations were higher in severe malaria, plasma concentrations of PfHRP2 were considerably higher in severe malaria (median titre 1:320, range zero to 1:1280) than in uncomplicated malaria (median titre 1:5, range zero to 1:80; P < 0.0001). The ratio of whole blood to plasma PfHRP2 was lower in severe than in uncomplicated malaria (median 4, range 0.25 to 256, versus 64, range 4 to 1280; P < 0.0001). With plasma samples the intensity of colour change on the dipstick correlated well with more precise measurement of optical density in the ELISA (r = 0.88, P < 0.0001). These results suggest that measurement of PfHRP2 in plasma could provide an alternative approach to the assessment of the parasite biomass, and thus prognosis, in severe malaria, and that this could be done simply by using the currently available dipsticks.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373661     DOI: 10.1016/s0035-9203(97)90292-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  31 in total

1.  Histidine-rich protein II: a novel approach to malaria drug sensitivity testing.

Authors:  Harald Noedl; Walther H Wernsdorfer; Robert Scott Miller; Chansuda Wongsrichanalai
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing.

Authors:  Harald Noedl; Jan Bronnert; Kritsanai Yingyuen; Bernhard Attlmayr; Herwig Kollaritsch; Mark Fukuda
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Detection of the Plasmodium falciparum antigen histidine-rich protein 2 in blood of pregnant women: implications for diagnosing placental malaria.

Authors:  R F Leke; R R Djokam; R Mbu; R J Leke; J Fogako; R Megnekou; S Metenou; G Sama; Y Zhou; T Cadigan; M Parra; D W Taylor
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia.

Authors:  E Tjitra; S Suprianto; M Dyer; B J Currie; N M Anstey
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 5.  Methodology and application of flow cytometry for investigation of human malaria parasites.

Authors:  Brian T Grimberg
Journal:  J Immunol Methods       Date:  2011-02-04       Impact factor: 2.303

Review 6.  Dynamic interactions of Plasmodium spp. with vascular endothelium.

Authors:  Mark R Gillrie; May Ho
Journal:  Tissue Barriers       Date:  2016-12-07

7.  Histidine-rich protein 2 plasma levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection.

Authors:  Lindsay L Fox; Terrie E Taylor; Paul Pensulo; Alice Liomba; Ashley Mpakiza; Amanda Varela; Simon J Glover; Mathew J Reeves; Karl B Seydel
Journal:  J Infect Dis       Date:  2013-04-22       Impact factor: 5.226

8.  Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria.

Authors:  Thiranut Ramutton; Ilse C E Hendriksen; Juliet Mwanga-Amumpaire; George Mtove; Rasaq Olaosebikan; Antoinette K Tshefu; Marie A Onyamboko; Corine Karema; Kathryn Maitland; Ermelinda Gomes; Samwel Gesase; Hugh Reyburn; Kamolrat Silamut; Kesinee Chotivanich; Kamoltip Promnares; Caterina I Fanello; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White; Arjen M Dondorp; Mallika Imwong; Charles J Woodrow
Journal:  Malar J       Date:  2012-08-16       Impact factor: 2.979

9.  PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria.

Authors:  Sandrine Houzé; Mainoumata Dicko Boly; Jacques Le Bras; Philippe Deloron; Jean-François Faucher
Journal:  Malar J       Date:  2009-09-07       Impact factor: 2.979

10.  Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma, and serum.

Authors:  Carolyne M Kifude; Halli G Rajasekariah; David J Sullivan; V Ann Stewart; Evelina Angov; Samuel K Martin; Carter L Diggs; John N Waitumbi
Journal:  Clin Vaccine Immunol       Date:  2008-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.